ORIONS Money Stocks

[Wrinkles]

TTNP .725 - Phase 3 Data Probuphine for Opioid dependence, in response to CRL, due 2nd qtr 2015, NDA due late 2015....link below....

Should be getting close to making that climb to a buck, forward looking catalyst getting closer.......

http://stockcharts.com/h-sc/ui?s=ttnp

http://finance.yahoo.com/news/titan-pharmaceuticals-reports-fourth-quarter-110000009.html

"Titan saw significant progress in 2014 both with the Probuphine development program for the maintenance treatment of opioid dependence and in advancing our ProNeura™-based non-clinical program for Parkinson's disease. Having reached agreement with the FDA in early 2014 on the Probuphine clinical study design, Braeburn expeditiously commenced the clinical study and completed full patient enrollment in November, almost two months ahead of an already aggressive schedule," said Titan President Sunil Bhonsle. "Importantly, we look forward to results from the Probuphine trial by the end of the second quarter this year and resubmitting the NDA in the second half of 2015. If approved, Probuphine would be the first and only commercialized treatment for opioid dependence to provide continuous, round-the-clock blood levels of buprenorphine for six months, bringing a much-needed treatment option to the millions of patients suffering from this terrible illness."